QPT — Quest PharmaTech Income Statement
0.000.00%
Last trade - 00:00- CA$8.46m
- CA$9.25m
- 50
- 84
- 76
- 80
Annual income statement for Quest PharmaTech, fiscal year end - January 31st, CAD millions except per share, conversion factor applied.
2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | 2025 January 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS/A | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | -127 | 0.521 | 0.384 | 1.16 | 0.517 |
| Operating Profit | 127 | -0.521 | -0.384 | -1.16 | -0.517 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 190 | -85 | -64.9 | -3.02 | -1.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 190 | -85 | -64.9 | -3.02 | -1.8 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | 190 | -85 | -64.9 | -3.02 | -1.8 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 190 | -85 | -64.9 | -3.02 | -1.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.367 | -0.507 | -0.388 | -0.019 | -0.012 |